Acquired idiopathic inflammatory myopathy

This study tests a new treatment called rapcabtagene autoleucel for people with severe idiopathic inflammatory myopathies (muscle inflammation) that hasn't improved with standard therapies. About 21 adults will receive either this cell therapy or a comparator. The main goal is to…

This study tests the long-term safety of a drug called efgartigimod PH20 SC in adults with active idiopathic inflammatory myopathy, a group of rare muscle diseases. Participants who completed a previous trial will receive the drug as a shot under the skin for up to 51 months. The…

This early-phase trial tests a new cell therapy called BEN301 for several autoimmune diseases, including scleroderma and rheumatoid arthritis. The therapy uses specially engineered immune cells (CAR-Treg cells) to calm the overactive immune system. The study involves 24 adults an…

This phase 2 trial tests whether nipocalimab, given intravenously, can improve symptoms of active idiopathic inflammatory myopathies (myositis) better than a placebo. About 36 adults with myositis will receive either nipocalimab or a placebo, along with standard steroid treatment…

This study is a long-term extension of an earlier trial, testing the safety of a drug called RAY121 in people with six different immune system disorders, including antiphospholipid syndrome and immune thrombocytopenia. Participants have already completed four doses of RAY121 and …

This early-phase study tests a new treatment called Prula-cel for people with autoimmune diseases like lupus, scleroderma, and vasculitis. Prula-cel uses donor immune cells engineered to target and destroy faulty immune cells that attack the body. The goal is to find a safe dose …

This study was designed to test a new treatment for people with autoimmune diseases like lupus, scleroderma, and myositis. It combined a specially engineered immune cell product (CLBR001) with a targeted antibody drug (SWI019), with or without a preparatory chemotherapy step. How…

This study tests whether adding intravenous immunoglobulin (IVIg) to standard steroid treatment early in myositis helps patients improve faster. Myositis is a group of rare diseases causing muscle inflammation and weakness. The trial includes 44 adults diagnosed within the past y…

This early-stage trial is testing a new treatment called KYV-101 for people with severe autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves taking a patient's own immune cells, modifying them to target and destroy faulty B cells, and giving them ba…

This early-phase trial is testing a CAR-T cell therapy called RD06-04 in 12 people with active autoimmune diseases like lupus, scleroderma, and vasculitis. The treatment involves reprogramming a patient's own immune cells to target and destroy faulty B cells. The main goal is to …

This early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…

This early-stage study is testing a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't improved with standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy f…

This study tests whether a pharmacist-led program can help people reduce their risk of heart disease. Over 1,000 adults with conditions like diabetes, high blood pressure, or obesity are taking part. Pharmacists use a step-by-step guide to assess risk and support lifestyle change…

This study planned to test deucravacitinib, a drug already approved for psoriasis, in adults with hard-to-treat dermatomyositis (DM) or juvenile dermatomyositis (JDM). Participants would have taken a pill twice daily for 24 weeks, with clinic visits every 4 weeks. However, the st…

This phase 3 trial tests an oral drug called brepocitinib in 241 adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Participants receive either the drug or a placebo for 52 weeks to see if it improves symptoms. The study is active but no longer rec…

This study tests a drug called empasiprubart in adults with dermatomyositis, a rare disease causing muscle weakness and skin rash. Three participants receive either the drug or a placebo for 25 weeks, then are followed for 65 more weeks. The goal is to see if the drug is safe and…

This study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…

This study follows up to 500 people with acute or chronic inflammatory disorders, such as infections or immune problems, over time. Researchers will monitor participants with standard tests and may screen them for other studies. The goal is to better understand these conditions a…

This study aims to create a tool that predicts which patients with inflammatory rheumatic diseases (like rheumatoid arthritis, vasculitis, or polymyalgia rheumatica) will develop serious side effects from long-term steroid use. Researchers will collect routine medical data—such a…

This study looked at whether having more frequent contact with a clinician (at least once a week) improves satisfaction for people with long-lasting musculoskeletal conditions. Participants were split into two groups: one with standard contact and one with extra check-ins via tex…

This study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…

This study tests whether a Norwegian clinic (NSAC) helps people with common mental health issues or muscle pain return to work sooner. 2500 adults are split into three groups: one gets treatment quickly, one waits 10-14 weeks, and one gets a basic check-up. Researchers will track…

This study examines blood samples from 50 people with dermatomyositis, an autoimmune disease that raises the risk of cancer. Researchers are looking for new antibodies and immune molecules that might signal which patients are more likely to develop cancer. The goal is to improve …

This study looks at 200 people with dermatomyositis, a rare muscle disease that often affects the lungs. Researchers are using special PET/CT scans and machine learning to create a model that can better predict if a patient has interstitial lung disease. The goal is to improve di…

This study was designed to track pregnancies in women with rare autoimmune and systemic diseases to understand complications and improve care. It planned to enroll women with conditions like lupus, rheumatoid arthritis, and scleroderma. However, the study was withdrawn before any…

This study looks back at the medical records of about 4 million people who had physical or occupational therapy for muscle and joint problems. Researchers want to see if different ways of giving therapy lead to different results. No new treatments are tested—the goal is to learn …

This study aimed to see if a mobile monitoring tool could accurately identify surgical site infections (SSIs) in orthopedic surgery patients, compared to the usual manual review. The study was withdrawn before enrolling any participants, so no results are available. It was design…